Secukinumab provides better relief from the impact of psoriasis on daily activities and personal relationships than etanercept: results of two phase 3 placebo-controlled randomized clinical trials in moderate-to-severe psoriasis

Neil J. Korman, Howard Sofen, Scott Fretzin, Phoebe Rich, Yang Zhao, Vivian Herrera, Judit Nyirady, Nicole Williams, Margaret Mordin, Stephen Tyring

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Psoriasis can greatly impact patients’ lives, influencing what clothing they wear and impairing their sexual functioning. Objective: To provide a detailed comparison of the impact of secukinumab vs. etanercept on enabling patients with psoriasis to have more normal lives with respect to daily activities (DA) (e.g. choosing clothing) and personal relationships (PR) (e.g. sexual functioning). Methods: Baseline to Week 52 ERASURE and FIXTURE data for secukinumab 300 mg and etanercept were analyzed. Treatment differences in mean scores on the DA and PR subscales and items from the Dermatology Life Quality Index were compared. The proportions of subscale and item responders (score = 0) were compared. Results: Subjects receiving secukinumab (n = 572) achieved greater mean improvement in DA and items (q3 and q4) than subjects receiving etanercept (n = 326; all p <.01 through Week 52). Subjects receiving secukinumab achieved greater mean improvement in PR and items (q8 and q9) than subjects receiving etanercept (subscale: p <.05 at Weeks 8 and 12). Response rates were significantly higher for secukinumab than for etanercept for DA (all p <.0001) and PR (all p <.05 except Weeks 4 and 36). Conclusions: Secukinumab 300 mg provides greater improvements and more effective relief from psoriasis impact on DA and PR than etanercept.

Original languageEnglish (US)
Pages (from-to)384-389
Number of pages6
JournalJournal of Dermatological Treatment
Volume28
Issue number5
DOIs
StatePublished - Jul 4 2017
Externally publishedYes

Fingerprint

Psoriasis
Randomized Controlled Trials
Placebos
Clothing
Dermatology
Etanercept
secukinumab
Quality of Life

Keywords

  • clothing choice
  • daily activities
  • DLQI
  • health-related quality of life
  • personal relationships
  • Psoriasis
  • secukinumab

ASJC Scopus subject areas

  • Dermatology

Cite this

Secukinumab provides better relief from the impact of psoriasis on daily activities and personal relationships than etanercept : results of two phase 3 placebo-controlled randomized clinical trials in moderate-to-severe psoriasis. / Korman, Neil J.; Sofen, Howard; Fretzin, Scott; Rich, Phoebe; Zhao, Yang; Herrera, Vivian; Nyirady, Judit; Williams, Nicole; Mordin, Margaret; Tyring, Stephen.

In: Journal of Dermatological Treatment, Vol. 28, No. 5, 04.07.2017, p. 384-389.

Research output: Contribution to journalArticle

Korman, Neil J. ; Sofen, Howard ; Fretzin, Scott ; Rich, Phoebe ; Zhao, Yang ; Herrera, Vivian ; Nyirady, Judit ; Williams, Nicole ; Mordin, Margaret ; Tyring, Stephen. / Secukinumab provides better relief from the impact of psoriasis on daily activities and personal relationships than etanercept : results of two phase 3 placebo-controlled randomized clinical trials in moderate-to-severe psoriasis. In: Journal of Dermatological Treatment. 2017 ; Vol. 28, No. 5. pp. 384-389.
@article{1458f4fd3ba749db9cad776cde4cbc87,
title = "Secukinumab provides better relief from the impact of psoriasis on daily activities and personal relationships than etanercept: results of two phase 3 placebo-controlled randomized clinical trials in moderate-to-severe psoriasis",
abstract = "Background: Psoriasis can greatly impact patients’ lives, influencing what clothing they wear and impairing their sexual functioning. Objective: To provide a detailed comparison of the impact of secukinumab vs. etanercept on enabling patients with psoriasis to have more normal lives with respect to daily activities (DA) (e.g. choosing clothing) and personal relationships (PR) (e.g. sexual functioning). Methods: Baseline to Week 52 ERASURE and FIXTURE data for secukinumab 300 mg and etanercept were analyzed. Treatment differences in mean scores on the DA and PR subscales and items from the Dermatology Life Quality Index were compared. The proportions of subscale and item responders (score = 0) were compared. Results: Subjects receiving secukinumab (n = 572) achieved greater mean improvement in DA and items (q3 and q4) than subjects receiving etanercept (n = 326; all p <.01 through Week 52). Subjects receiving secukinumab achieved greater mean improvement in PR and items (q8 and q9) than subjects receiving etanercept (subscale: p <.05 at Weeks 8 and 12). Response rates were significantly higher for secukinumab than for etanercept for DA (all p <.0001) and PR (all p <.05 except Weeks 4 and 36). Conclusions: Secukinumab 300 mg provides greater improvements and more effective relief from psoriasis impact on DA and PR than etanercept.",
keywords = "clothing choice, daily activities, DLQI, health-related quality of life, personal relationships, Psoriasis, secukinumab",
author = "Korman, {Neil J.} and Howard Sofen and Scott Fretzin and Phoebe Rich and Yang Zhao and Vivian Herrera and Judit Nyirady and Nicole Williams and Margaret Mordin and Stephen Tyring",
year = "2017",
month = "7",
day = "4",
doi = "10.1080/09546634.2016.1255306",
language = "English (US)",
volume = "28",
pages = "384--389",
journal = "Journal of Dermatological Treatment",
issn = "0954-6634",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Secukinumab provides better relief from the impact of psoriasis on daily activities and personal relationships than etanercept

T2 - results of two phase 3 placebo-controlled randomized clinical trials in moderate-to-severe psoriasis

AU - Korman, Neil J.

AU - Sofen, Howard

AU - Fretzin, Scott

AU - Rich, Phoebe

AU - Zhao, Yang

AU - Herrera, Vivian

AU - Nyirady, Judit

AU - Williams, Nicole

AU - Mordin, Margaret

AU - Tyring, Stephen

PY - 2017/7/4

Y1 - 2017/7/4

N2 - Background: Psoriasis can greatly impact patients’ lives, influencing what clothing they wear and impairing their sexual functioning. Objective: To provide a detailed comparison of the impact of secukinumab vs. etanercept on enabling patients with psoriasis to have more normal lives with respect to daily activities (DA) (e.g. choosing clothing) and personal relationships (PR) (e.g. sexual functioning). Methods: Baseline to Week 52 ERASURE and FIXTURE data for secukinumab 300 mg and etanercept were analyzed. Treatment differences in mean scores on the DA and PR subscales and items from the Dermatology Life Quality Index were compared. The proportions of subscale and item responders (score = 0) were compared. Results: Subjects receiving secukinumab (n = 572) achieved greater mean improvement in DA and items (q3 and q4) than subjects receiving etanercept (n = 326; all p <.01 through Week 52). Subjects receiving secukinumab achieved greater mean improvement in PR and items (q8 and q9) than subjects receiving etanercept (subscale: p <.05 at Weeks 8 and 12). Response rates were significantly higher for secukinumab than for etanercept for DA (all p <.0001) and PR (all p <.05 except Weeks 4 and 36). Conclusions: Secukinumab 300 mg provides greater improvements and more effective relief from psoriasis impact on DA and PR than etanercept.

AB - Background: Psoriasis can greatly impact patients’ lives, influencing what clothing they wear and impairing their sexual functioning. Objective: To provide a detailed comparison of the impact of secukinumab vs. etanercept on enabling patients with psoriasis to have more normal lives with respect to daily activities (DA) (e.g. choosing clothing) and personal relationships (PR) (e.g. sexual functioning). Methods: Baseline to Week 52 ERASURE and FIXTURE data for secukinumab 300 mg and etanercept were analyzed. Treatment differences in mean scores on the DA and PR subscales and items from the Dermatology Life Quality Index were compared. The proportions of subscale and item responders (score = 0) were compared. Results: Subjects receiving secukinumab (n = 572) achieved greater mean improvement in DA and items (q3 and q4) than subjects receiving etanercept (n = 326; all p <.01 through Week 52). Subjects receiving secukinumab achieved greater mean improvement in PR and items (q8 and q9) than subjects receiving etanercept (subscale: p <.05 at Weeks 8 and 12). Response rates were significantly higher for secukinumab than for etanercept for DA (all p <.0001) and PR (all p <.05 except Weeks 4 and 36). Conclusions: Secukinumab 300 mg provides greater improvements and more effective relief from psoriasis impact on DA and PR than etanercept.

KW - clothing choice

KW - daily activities

KW - DLQI

KW - health-related quality of life

KW - personal relationships

KW - Psoriasis

KW - secukinumab

UR - http://www.scopus.com/inward/record.url?scp=84996524196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84996524196&partnerID=8YFLogxK

U2 - 10.1080/09546634.2016.1255306

DO - 10.1080/09546634.2016.1255306

M3 - Article

C2 - 27832717

AN - SCOPUS:84996524196

VL - 28

SP - 384

EP - 389

JO - Journal of Dermatological Treatment

JF - Journal of Dermatological Treatment

SN - 0954-6634

IS - 5

ER -